Johnson & Johnson's Erleada plus ADT cuts prostate cancer recurrence or death risk 62% versus surgery alone
JNJ•Johnson & Johnson said perioperative Erleada plus hormone therapy reduced the risk of prostate cancer recurrence or death by 62% versus surgery alone in a Phase 3 PROTEUS substudy. The regimen delayed subsequent treatment, but severe adverse events were more frequent and the use remains unapproved.
1. PROTEUS substudy results
Johnson & Johnson announced that perioperative Erleada with hormone therapy reduced recurrence or death risk by 62% versus surgery alone in high-risk localized or locally advanced prostate cancer. The regimen also delayed subsequent treatment and showed a numerical improvement in survival without metastasis; severe adverse events were more frequent, the use remains unapproved, and overall survival follow-up continues.
